Company Intelligence
Maven Bio is a 10-person seed-stage team in Boston building the market intelligence layer for life sciences AI. Three of the top 10 pharma companies are onboarded, and we have 20+ enterprise accounts across pharma, consulting,…
Maven Bio is a 10-person seed-stage team in Boston building the market intelligence layer for life sciences AI. Three of the top 10 pharma companies are onboarded, and we have 20+ enterprise accounts across pharma, consulting, and investing. Customers report a 40% reduction in low-level analytical work.
We are growing fast and heading for a Series A. Our buyers are senior BD, CI, Strategy, and Investing leaders.
The AI Platform for Life Sciences Intelligence
Maven Bio was founded in 2023 per the company profile source on file.
SourceA verified review of the enterprise AI landscape in 2026, covering automation, governed data platforms, and workplace assistants,…
View ReportA verified review of enterprise AI workflow automation from 2024 to 2026, covering the RPA-to-agentic transition, low-code process…
View ReportAn evergreen landscape report of 14 verified AI companies in Enterprise Software covered on Brel Digital, grounded in…
View ReportBased on operator interviews and market signals, this report maps how Fortune 500 companies are moving from pilots…
View ReportA verified look at how enterprise AI adoption evolved from 2024 to 2026, covering automation, generative…
Read InsightA verified guide to enterprise AI knowledge management companies, including Glean, Writer, Dataiku, and Moveworks, and…
Read InsightA verified 2026 look at enterprise AI workflow automation spending, covering RPA-to-agentic transitions, low-code platforms, and…
Read InsightA verified 2026 comparison of enterprise AI search and knowledge platforms, covering Glean, Moveworks, Writer, Dataiku,…
Read InsightMaven Bio is a 10-person seed-stage team in Boston building the market intelligence layer for life sciences AI. Three of the top 10 pharma companies are onboarded, and we have 20+ enterprise accounts across pharma, consulting, and investing. Customers report a 40% reduction in low-level analytical work.
We are growing fast and heading for a Series A. Our buyers are senior BD, CI, Strategy, and Investing leaders.
Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.
Request a correction if you represent this company or believe information is inaccurate.
